EKF Diagnostics Reports Strong 2024 Results and Unveils Five-Year Growth Plan

An update from EKF Diagnostics Holdings ( (GB:EKF) ) is now available.

EKF Diagnostics Holdings has reported its full-year results for 2024, highlighting a 9.2% growth in adjusted EBITDA and stronger than expected cash generation. The company has focused on higher margin product ranges and core operations, while winding down non-core and low margin product lines. This strategic shift has resulted in improved gross margins and a significant strengthening of its balance sheet. EKF has also announced a five-year strategic development plan aimed at accelerating growth, with a focus on reinvesting in its core business divisions to drive organic growth and margin improvement. The company is considering various options for utilizing its strong cash generation to deliver further value to shareholders.

More about EKF Diagnostics Holdings

EKF Diagnostics Holdings plc is an AIM-listed global diagnostics company specializing in Point-of-Care analyzers, particularly in Hematology and Diabetes, and Life Sciences services, which include the manufacture of enzymes and custom products for diagnostic, food, and industrial applications. The company operates five manufacturing sites across the US and Germany and sells its products in over 120 countries worldwide.

YTD Price Performance: -24.07%

Average Trading Volume: 399,122

Technical Sentiment Signal: Buy

Current Market Cap: £93.01M

See more data about EKF stock on TipRanks’ Stock Analysis page.